A detailed history of Vanguard Group Inc transactions in Neuro Pace Inc stock. As of the latest transaction made, Vanguard Group Inc holds 995,196 shares of NPCE stock, worth $8.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
995,196
Previous 967,716 2.84%
Holding current value
$8.94 Million
Previous $7.32 Million 5.18%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.65 - $8.46 $182,742 - $232,480
27,480 Added 2.84%
995,196 $6.94 Million
Q2 2024

Aug 13, 2024

BUY
$6.38 - $15.33 $3.06 Million - $7.34 Million
479,098 Added 98.05%
967,716 $7.32 Million
Q1 2024

May 10, 2024

BUY
$9.78 - $17.5 $738,507 - $1.32 Million
75,512 Added 18.28%
488,618 $6.45 Million
Q4 2023

Feb 14, 2024

BUY
$5.9 - $10.31 $159,423 - $278,586
27,021 Added 7.0%
413,106 $4.26 Million
Q3 2023

Nov 14, 2023

BUY
$4.0 - $9.73 $31,592 - $76,847
7,898 Added 2.09%
386,085 $3.76 Million
Q2 2023

Aug 14, 2023

BUY
$3.98 - $5.12 $324,923 - $417,991
81,639 Added 27.53%
378,187 $1.7 Million
Q1 2023

May 15, 2023

BUY
$1.44 - $5.34 $32,571 - $120,785
22,619 Added 8.26%
296,548 $1.38 Million
Q4 2022

Feb 10, 2023

BUY
$1.29 - $3.67 $171 - $488
133 Added 0.05%
273,929 $408,000
Q2 2022

Aug 12, 2022

SELL
$4.95 - $8.7 $184,001 - $323,396
-37,172 Reduced 11.95%
273,796 $1.36 Million
Q1 2022

May 13, 2022

SELL
$7.06 - $11.57 $861 - $1,411
-122 Reduced 0.04%
310,968 $2.55 Million
Q4 2021

Feb 14, 2022

BUY
$8.63 - $17.36 $145,199 - $292,082
16,825 Added 5.72%
311,090 $3.14 Million
Q3 2021

Nov 12, 2021

BUY
$15.85 - $25.07 $36,280 - $57,385
2,289 Added 0.78%
294,265 $4.66 Million
Q2 2021

Aug 13, 2021

BUY
$19.03 - $26.5 $5.56 Million - $7.74 Million
291,976 New
291,976 $6.95 Million

Others Institutions Holding NPCE

About NeuroPace Inc


  • Ticker NPCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,846,900
  • Market Cap $223M
  • Description
  • NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...
More about NPCE
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.